BRPI0414343A - combinações que compreendem ligantes de alfa-2-delta e inibidores da reabsorção de serotonina/noradrenalina - Google Patents
combinações que compreendem ligantes de alfa-2-delta e inibidores da reabsorção de serotonina/noradrenalinaInfo
- Publication number
- BRPI0414343A BRPI0414343A BRPI0414343-4A BRPI0414343A BRPI0414343A BR PI0414343 A BRPI0414343 A BR PI0414343A BR PI0414343 A BRPI0414343 A BR PI0414343A BR PI0414343 A BRPI0414343 A BR PI0414343A
- Authority
- BR
- Brazil
- Prior art keywords
- serotonin
- alpha
- combinations
- norepinephrine reuptake
- reuptake inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
"COMBINAçõES QUE COMPREENDEM LIGANTES DE ALFA-2-DELTA E INIBIDORES DA REABSORçãO DE SEROTONINA/NORADRENALINA". A presente invenção refere-se a uma combinação, particularmente uma combinação sinérgica, de um ligante de alfa-2-delta e um inibidor da reabsorção dupla de serotonina/noradrenalina (DSNRI) ou um ou ambos entre um inibidor seletivo da reabsorção de serotonina (SSRI) e um inibidor seletivo da reabsorção de noradrenalina (SNRI), e seus sais farmaceuticamente aceitáveis, suas composições farmacêuticas e seu uso no tratamento de dor, particularmente dor neuropática.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50255603P | 2003-09-12 | 2003-09-12 | |
PCT/IB2004/002943 WO2005025675A1 (en) | 2003-09-12 | 2004-09-06 | Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0414343A true BRPI0414343A (pt) | 2006-11-07 |
Family
ID=34312404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0414343-4A BRPI0414343A (pt) | 2003-09-12 | 2004-09-06 | combinações que compreendem ligantes de alfa-2-delta e inibidores da reabsorção de serotonina/noradrenalina |
Country Status (21)
Country | Link |
---|---|
US (4) | US20050059715A1 (pt) |
EP (2) | EP2156863A3 (pt) |
JP (2) | JP2007505097A (pt) |
KR (1) | KR100828218B1 (pt) |
CN (1) | CN1849153A (pt) |
AR (1) | AR045634A1 (pt) |
AT (1) | ATE449633T1 (pt) |
AU (2) | AU2004271800A1 (pt) |
BR (1) | BRPI0414343A (pt) |
CA (1) | CA2537402C (pt) |
CO (1) | CO5660280A2 (pt) |
DE (1) | DE602004024317D1 (pt) |
ES (1) | ES2334673T3 (pt) |
IL (1) | IL173904A0 (pt) |
MX (1) | MXPA06002789A (pt) |
NO (1) | NO20061083L (pt) |
NZ (1) | NZ545494A (pt) |
RU (1) | RU2320369C2 (pt) |
TW (1) | TW200526249A (pt) |
WO (1) | WO2005025675A1 (pt) |
ZA (1) | ZA200602077B (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1094757C (zh) | 1996-07-24 | 2002-11-27 | 沃尼尔·朗伯公司 | 用于治疗疼痛的异丁基γ-氨基丁酸及其衍生物 |
US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
AU2005256944A1 (en) * | 2004-06-09 | 2006-01-05 | Pfizer Inc. | Use of reboxetine for the treatment of pain |
WO2007088473A2 (en) * | 2006-02-03 | 2007-08-09 | Neurocure Ltd | Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain |
TW200914457A (en) * | 2007-05-31 | 2009-04-01 | Kyowa Hakko Kogyo Kk | Pyrimidodiazepinone derivative |
WO2009136375A1 (en) * | 2008-05-08 | 2009-11-12 | Pfizer Inc | Treatment of interstitial cystitis |
EP2123626A1 (en) | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
JP6163304B2 (ja) | 2009-07-15 | 2017-07-12 | ポートラ ファーマシューティカルズ, インコーポレイテッド | 第Xa因子インヒビターの解毒剤の単位用量処方物およびその使用方法 |
KR101786818B1 (ko) | 2010-07-30 | 2017-10-18 | 도레이 카부시키가이샤 | 신경장애성 동통의 치료제 또는 예방제 |
US10576045B2 (en) | 2011-02-16 | 2020-03-03 | Nir Barak | Low dosage combinations of fluoxetine and reboxetine for treating obesity |
US10004710B2 (en) | 2013-01-18 | 2018-06-26 | Kemphys Ltd. | Medicament for therapeutic treatment of neuropathic disease |
US9663479B2 (en) * | 2013-12-18 | 2017-05-30 | Novassay S.A. | γ-aminobutyric acid (GABA) analogues for the treatment of pain and other disorders |
MX2018004532A (es) | 2015-10-22 | 2018-09-12 | Acraf | Combinacion de trazodona y gabapentina para el tratamiento de dolor. |
IT201900006602A1 (it) | 2019-05-07 | 2020-11-07 | Acraf | Composizione farmaceutica per il trattamento del dolore neuropatico |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3454554A (en) | 1960-10-14 | 1969-07-08 | Colgate Palmolive Co | Aminoalkyliminodibenzyl compounds |
NL127069C (pt) | 1961-10-10 | |||
US3198834A (en) | 1964-07-27 | 1965-08-03 | Snc Science Union Et Compagnie | Optical isomers of trifluoromethylated phenethylamines |
NL129434C (pt) | 1966-03-12 | |||
GB1177525A (en) | 1967-04-13 | 1970-01-14 | Leo Ab | New Heterocyclic Aminoketones of Therapeutic Interest |
BE759838A (fr) | 1969-12-04 | 1971-06-03 | Wellcome Found | Cetones a activite biologique |
US3885046A (en) | 1969-12-04 | 1975-05-20 | Burroughs Wellcome Co | Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression |
GB1422263A (en) | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
US4626549A (en) | 1974-01-10 | 1986-12-02 | Eli Lilly And Company | Treatment of obesity with aryloxyphenylpropylamines |
US4018895A (en) | 1974-01-10 | 1977-04-19 | Eli Lilly And Company | Aryloxyphenylpropylamines in treating depression |
US4194009A (en) | 1974-01-10 | 1980-03-18 | Eli Lilly And Company | Aryloxyphenylpropylamines for obtaining a psychotropic effect |
US4314081A (en) | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
NL7503310A (nl) | 1975-03-20 | 1976-09-22 | Philips Nv | Verbindingen met antidepressieve werking. |
US4062843A (en) | 1976-12-29 | 1977-12-13 | G. D. Searle & Co. | 23-Hydroxy-3-oxo-24-norchola-4,17(20)-dien-21-oic acid γ-lactone and intermediates thereto |
IL56369A (en) | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
US4535186A (en) | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
DK149624C (da) | 1983-03-07 | 1987-02-02 | Ferrosan As | Fremgangsmaade til fremstilling af (+)-trans-3-((4-methoxyphenoxy)-methyl)-1-methyl-4-phenylpiperidin eller et farmaceutisk acceptabelt salt heraf ud fra en blanding af enantiomererne |
US4611078A (en) | 1983-10-26 | 1986-09-09 | American Home Products Corporation | Substituted phenylacetonitriles |
US4761501A (en) | 1983-10-26 | 1988-08-02 | American Home Products Corporation | Substituted phenylacetamides |
GB8419683D0 (en) | 1984-08-02 | 1984-09-05 | Erba Farmitalia | 3-substituted derivatives of 1-amino-2-hydroxy-propane |
GB8419963D0 (en) | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
GB8814057D0 (en) | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
EP0641330B1 (en) | 1992-05-20 | 2001-10-17 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
AU720628B2 (en) | 1996-02-07 | 2000-06-08 | Warner-Lambert Company | Novel cyclic amino acids as pharmaceutical agents |
NZ331142A (en) | 1996-03-14 | 2001-04-27 | Warner Lambert Co | Bridged cyclic amino acids as pharmaceutical agents |
NZ331143A (en) | 1996-03-14 | 2001-06-29 | Warner Lambert Co | Substituted cyclic amino acids as pharmaceutical agents |
US6372792B1 (en) | 1996-04-26 | 2002-04-16 | Guy Chouinard | Method for treating anxiety, anxiety disorders and insomnia |
CN1094757C (zh) * | 1996-07-24 | 2002-11-27 | 沃尼尔·朗伯公司 | 用于治疗疼痛的异丁基γ-氨基丁酸及其衍生物 |
BR9712651A (pt) | 1996-10-23 | 1999-10-26 | Warner Lambert Co | cidos gama-aminobutìricos substituìdos com agentes farmacêuticos. |
WO1998046601A1 (en) * | 1997-04-11 | 1998-10-22 | Eli Lilly And Company | Composition for treating pain |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US5942530A (en) * | 1997-08-28 | 1999-08-24 | Eli Lilly And Company | Method for treating pain |
PL199794B1 (pl) | 1997-10-27 | 2008-10-31 | Warner Lambert Co | Związki pośrednie do wytwarzania pochodnych cyklicznych aminokwasów |
AU759392B2 (en) | 1997-12-16 | 2003-04-10 | Warner-Lambert Company | 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
CN1210268C (zh) | 1997-12-16 | 2005-07-13 | 沃尼尔·朗伯公司 | ((环)烷基取代的)-γ-氨基丁酸衍生物(=GABA类似物),其制备和在治疗神经病中的用途 |
PL341291A1 (en) | 1997-12-16 | 2001-04-09 | Warner Lambert Co | 1-substituted derivatives of 1-aminomethyl-ccycloalkanes (gabapentin analogues), their production and application of them in treating neurological disorders |
DK1089976T3 (da) * | 1998-06-22 | 2004-01-19 | Neurosearch As | Fremgangsmåde til fremstilling af 5-bromisoquinolin og dets 8-nitroderivat |
NZ512910A (en) | 1999-02-23 | 2003-11-28 | Pfizer Prod Inc | Monoamine reuptake inhibitors for treatment of CNS disorders |
JP3547360B2 (ja) | 1999-03-30 | 2004-07-28 | 株式会社東芝 | フィールドエミッション型表示装置及びその駆動方法 |
HUP0200733A3 (en) * | 1999-04-09 | 2003-04-28 | Warner Lambert Co | Combinations of gaba analogs and tricyclic compounds to treat depression |
CN1196671C (zh) | 1999-06-10 | 2005-04-13 | 沃尼尔·朗伯公司 | 单和双取代的3-丙基-γ-氨基丁酸 |
US20020022662A1 (en) * | 1999-06-15 | 2002-02-21 | American Home Products Corporation | Enantiomers of O-desmethyl venlafaxine |
DE60035232T2 (de) * | 1999-07-01 | 2008-02-14 | Pharmacia & Upjohn Co. Llc, Kalamazoo | (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom |
HN2000000224A (es) | 1999-10-20 | 2001-04-11 | Warner Lambert Co | Aminoacidos biciclicos como agentes farmaceuticos |
GB2362646A (en) | 2000-05-26 | 2001-11-28 | Warner Lambert Co | Cyclic amino acid derivatives useful as pharmaceutical agents |
GB2365425A (en) | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
ES2252310T3 (es) | 2000-09-14 | 2006-05-16 | Grunenthal Gmbh | Beta-tioaminoacidos. |
DE10048715A1 (de) | 2000-09-30 | 2004-05-19 | Grünenthal GmbH | Verwendung von Aminosäure zur Behandlung von Schmerz |
PE20021046A1 (es) | 2000-09-30 | 2002-12-14 | Gruenenthal Chemie | Sulfonilguanidina que tiene afinidad al punto de fijacion de gabapentina |
AU2002211863A1 (en) | 2000-10-06 | 2002-04-15 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
GB2367869B (en) | 2000-10-14 | 2004-10-06 | Trw Ltd | Rear-axle demand for use with front push-through in electrohydraulic (EHB) braking systems |
GB2368579A (en) | 2000-10-31 | 2002-05-08 | Parke Davis & Co Ltd | Azole pharmaceutical agents |
WO2002042414A2 (en) | 2000-11-17 | 2002-05-30 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
US6500972B2 (en) * | 2001-01-03 | 2002-12-31 | Chinese Petroleim Corp. | Synthesis of TMBQ with transition metal-containing molecular sieve as catalysts |
US6500955B1 (en) * | 2001-02-02 | 2002-12-31 | National Institute Of Pharmaceutical Education And Research | One pot synthesis of [2,8-Bis (trifluoromethyl)-4-quinolinyl]-2-pyridinylmethanone, a mefloquine intermediate |
OA12504A (en) | 2001-04-19 | 2006-05-29 | Warner Lambert Co | Fused bicyclic or tricyclic amino acids. |
AU783516B2 (en) * | 2001-04-30 | 2005-11-03 | Warner-Lambert Company | Methods, kits and compositions for using pyrrole derivatives |
SK286227B6 (sk) * | 2001-05-25 | 2008-05-06 | Warner-Lambert Company Llc | Kvapalná farmaceutická kompozícia obsahujúca analóg GABA a spôsob jej prípravy a použitie |
MXPA03011566A (es) | 2001-06-11 | 2004-10-28 | Xenoport Inc | Formas de dosificacion de profarmacos de analogos de gaba administrados oralmente que tienen toxicidad reducida. |
ITMI20011308A1 (it) | 2001-06-21 | 2002-12-21 | Nicox Sa | Farmaci per il dolore cronico |
US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
CA2473536A1 (en) * | 2002-01-16 | 2003-07-31 | Endo Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating disorders of the central nervous system |
WO2003066040A1 (fr) * | 2002-02-05 | 2003-08-14 | Ajinomoto Co.,Inc. | Compositions medicinales contenant une gabapentine ou une pregabaline et antagoniste a canal de calcium de type n |
JP2005523281A (ja) * | 2002-02-22 | 2005-08-04 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | アルファ−2−デルタリガンドとシクロオキシゲナーゼ−2の選択的阻害剤との組合せ |
ES2341240T3 (es) * | 2002-12-13 | 2010-06-17 | Warner-Lambert Company Llc | Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior. |
-
2004
- 2004-09-06 KR KR1020067004976A patent/KR100828218B1/ko not_active IP Right Cessation
- 2004-09-06 CA CA002537402A patent/CA2537402C/en not_active Expired - Fee Related
- 2004-09-06 WO PCT/IB2004/002943 patent/WO2005025675A1/en active Application Filing
- 2004-09-06 AT AT04769341T patent/ATE449633T1/de not_active IP Right Cessation
- 2004-09-06 MX MXPA06002789A patent/MXPA06002789A/es active IP Right Grant
- 2004-09-06 DE DE602004024317T patent/DE602004024317D1/de active Active
- 2004-09-06 JP JP2006525924A patent/JP2007505097A/ja not_active Withdrawn
- 2004-09-06 AU AU2004271800A patent/AU2004271800A1/en not_active Abandoned
- 2004-09-06 CN CNA2004800261754A patent/CN1849153A/zh active Pending
- 2004-09-06 EP EP09176933A patent/EP2156863A3/en not_active Ceased
- 2004-09-06 ES ES04769341T patent/ES2334673T3/es active Active
- 2004-09-06 EP EP04769341A patent/EP1663398B1/en not_active Not-in-force
- 2004-09-06 RU RU2006107552/15A patent/RU2320369C2/ru not_active IP Right Cessation
- 2004-09-06 BR BRPI0414343-4A patent/BRPI0414343A/pt not_active IP Right Cessation
- 2004-09-06 NZ NZ545494A patent/NZ545494A/en not_active IP Right Cessation
- 2004-09-08 US US10/935,824 patent/US20050059715A1/en not_active Abandoned
- 2004-09-10 TW TW093127537A patent/TW200526249A/zh unknown
- 2004-09-10 AR ARP040103262A patent/AR045634A1/es not_active Application Discontinuation
-
2006
- 2006-02-23 IL IL173904A patent/IL173904A0/en unknown
- 2006-03-03 CO CO06021162A patent/CO5660280A2/es not_active Application Discontinuation
- 2006-03-06 NO NO20061083A patent/NO20061083L/no not_active Application Discontinuation
- 2006-03-10 ZA ZA200602077A patent/ZA200602077B/en unknown
-
2009
- 2009-12-02 US US12/629,516 patent/US20100081718A1/en not_active Abandoned
-
2011
- 2011-02-21 AU AU2011200717A patent/AU2011200717A1/en not_active Abandoned
-
2012
- 2012-03-07 JP JP2012049988A patent/JP2012144545A/ja not_active Withdrawn
- 2012-08-29 US US13/597,462 patent/US20120329781A1/en not_active Abandoned
-
2014
- 2014-03-19 US US14/219,351 patent/US20140206670A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE449633T1 (de) | 2009-12-15 |
WO2005025675A1 (en) | 2005-03-24 |
RU2006107552A (ru) | 2007-09-20 |
US20120329781A1 (en) | 2012-12-27 |
MXPA06002789A (es) | 2006-06-14 |
ES2334673T3 (es) | 2010-03-15 |
TW200526249A (en) | 2005-08-16 |
EP1663398A1 (en) | 2006-06-07 |
RU2320369C2 (ru) | 2008-03-27 |
EP2156863A2 (en) | 2010-02-24 |
ZA200602077B (en) | 2007-06-27 |
CA2537402A1 (en) | 2005-03-24 |
US20100081718A1 (en) | 2010-04-01 |
CA2537402C (en) | 2009-05-05 |
CO5660280A2 (es) | 2006-07-31 |
DE602004024317D1 (de) | 2010-01-07 |
NZ545494A (en) | 2009-10-30 |
KR20060082861A (ko) | 2006-07-19 |
US20050059715A1 (en) | 2005-03-17 |
AR045634A1 (es) | 2005-11-02 |
CN1849153A (zh) | 2006-10-18 |
EP2156863A3 (en) | 2011-01-12 |
AU2011200717A1 (en) | 2011-03-10 |
IL173904A0 (en) | 2006-07-05 |
JP2012144545A (ja) | 2012-08-02 |
EP1663398B1 (en) | 2009-11-25 |
KR100828218B1 (ko) | 2008-05-07 |
AU2004271800A1 (en) | 2005-03-24 |
NO20061083L (no) | 2006-06-06 |
US20140206670A1 (en) | 2014-07-24 |
JP2007505097A (ja) | 2007-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0414343A (pt) | combinações que compreendem ligantes de alfa-2-delta e inibidores da reabsorção de serotonina/noradrenalina | |
RS20050392A (en) | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | |
TW200505423A (en) | Combination, kit and pharmaceutical composition for treatment of parkinson's disease | |
EP2343073A3 (en) | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression | |
BRPI0408902A (pt) | composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca | |
CA2640451A1 (en) | Medicine for transnasal administration | |
BRPI0415007A (pt) | método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica | |
ECSP066516A (es) | Formulaciones farmacéuticas, procedimientos y pautas de dosificación para el tratamiento y prevención de síndromes coronarios agudos | |
BR0304648A (pt) | Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia | |
BRPI0510515A (pt) | compostos de morfolina | |
BR0312165A (pt) | Utilização da taurina para o tratamento da alopecia | |
BRPI0508596A (pt) | combinação compreendendo ligante alfa-2-delta | |
DE60323765D1 (de) | Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten | |
BRPI0514296A (pt) | combinação de um inibidor seletivo da recaptação de noradrenalina e um inibidor da pdev | |
ITRM20050514A1 (it) | Olio ozonizzato, principio attivo di elevata stabilita' a base di perossidi utilizzabile per applicazioni terapeutiche mediche e per trattamenti domiciliari similari a quelli dell'ozonoterapia, senza l'utilizzo di ozono gassoso. | |
DE60209152D1 (de) | Pharmazeutische zusammensetzung, umfassend gabapentin oder ein analogon davon und ein alpha-aminoamid | |
EA200702282A1 (ru) | Комбинация феррохина и производного артемизинина для лечения малярии | |
DK1370260T3 (da) | Azoler, som malonyl-coa-decarboxylaseinhibitorer anvendelige som mataboliske modulatorer | |
BRPI0510137A (pt) | medicamentos contendo n-sulfamoil-n'-arilpiperazinas para a profilaxia ou tratamento da obesidade e condições relacionadas | |
EP1254668A3 (en) | Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression | |
PA8571901A1 (es) | Nueva composicion farmaceutica | |
BR0206819A (pt) | Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca | |
BR0108980A (pt) | Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina | |
AR045423A1 (es) | Combinaciones de analiticos y antidepresivos | |
WO2004100939B1 (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2270 DE 08/07/2014. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 45/06 (2006.01), A61P 29/00 (2006.01), A61P 2 |